Clinical Trial Search

Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale

Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013

Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…

Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale

Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants

Primary: Nasal Congestion as Assessed by the Peak Nasal Inspiratory Flow (PNIF) — 90 Liters Per Minute

Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Primary: Number of Participants With Procedure-related Serious Adverse Events (SAEs) and/or Serious Adverse Device Effects (SADE) — 0 Participants

Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants

Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils

Primary: Change in Reflective Total Nasal Symptom Score (rTNSS) — -5.1 units on a scale — p=<0.0001

Primary: Reflective Total Nasal Symptom Score (rTNSS) Responder Rate — 52; 16 Participants

Primary: Sinonasal Outcome Test (SNOT 20) — 50.33; 53.14; 37 Score out of total 100

Primary: Mean Change of the Reflective Total Nasal Symptoms Score (rTNSS) — -4.2 Change in rTNSS score from baseline

Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 — 5.190; 4.071; 3.840 Scores on a scale — p=<0.0001

Primary: Change in Nasal Polyp Score — .9; .3 score on a scale

Primary: Change From Baseline in Symptom Severity — -3.1 score on a scale — p=<0.001

Primary: Change in Total Symptom Score — -5; 2 score on a scale

Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001

Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05

Primary: Total Nasal Symptom Scores — 3.0; 3.1 score on a scale — p=0.45

Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)

Primary: Morning "AM" Serum Cortisol Level — 17.35; 14.48 mcg/dL

Primary: The Change From Baseline in the Mean of the 3 Single Symptom Scores (Blocked Nose, Sneezing and Running Nose) at the Closing/Final Visit. — -2 units on a scale

Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale

Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale

Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…

Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391